The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,595
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase
Nidai Ozes, O., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999) · Nature · doi:10.1038/43466 · Cited by 1,832
Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt
Peso, L. D., González-Garcı́a, M., Page, C., Herrera, R., & Nuñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 1,797
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs
Obenauer, J. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg584 · Cited by 1,596
NF-κB is a target of AKT in anti-apoptotic PDGF signalling
Romashkova, J. A., & Makarov, S. S. (1999) · Nature · doi:10.1038/43474 · Cited by 1,517
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Delcommenne, M., Tan, C., Gray, V., Rue, L., Woodgett, J., & Dedhar, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11211 · Cited by 1,092
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., Lee, J.-H., Ciarallo, S., Catzavelos, C., Beniston, R., et al. (2002) · Nature Medicine · doi:10.1038/nm761 · Cited by 948
SEHGAL, S. N., BAKER, H., & VÉZINA, C. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.727 · Cited by 947
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Shin, I., Yakes, F. M., Rojo, F., Shin, N.-Y., Bakin, A. V., Baselga, J., & Arteaga, C. L. (2002) · Nature Medicine · doi:10.1038/nm759 · Cited by 790
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Thomson, S., Buck, E., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663
Majewski, N., Nogueira, V., Bhaskar, P., Coy, P. E., Skeen, J. E., Gottlob, K., Chandel, N. S., Thompson, C. B., Robey, R. B., & Hay, N. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.014 · Cited by 633
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Brognard, J., Sierecki, E., Gao, T., & Newton, A. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.017 · Cited by 591
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition
Irie, H. Y., Pearline, R. V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, N., Natesan, S., & Brugge, J. S. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505087 · Cited by 589
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
West, K. A., Sianna Castillo, S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 585
Self-citationA dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity
Ali, I. U., Schriml, L. M., & Dean, M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1922 · Cited by 542
Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G. B., & Kondo, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3640 · Cited by 534
(1998) · PubMed · Cited by 525
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
Akt/Protein Kinase B Is Regulated by Autophosphorylation at the Hypothetical PDK-2 Site
Toker, A., & Newton, A. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8271 · Cited by 516
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
Yauch, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., Pham, T. Q., Soriano, R., Stinson, J., Seshagiri, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1492 · Cited by 495
Engelman, J. A., Jänne, P. A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 493
Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase
Feng, J., Park, J., Cron, P., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406731200 · Cited by 488
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 456
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.
Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 455
Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 448
Self-citationPIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
Balendran, A., Casamayor, A., Deak, M., Paterson, A., Gaffney, P., Currie, R., Downes, C. P., & Alessi, D. R. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80186-9 · Cited by 429
Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 422
She, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 421
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
and members of the Southeast Sweden Breast Cancer Group, Pérez-Tenorio, G., & Stål, O. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600126 · Cited by 394
PTEN gene mutations are seen in high-grade but not in low-grade gliomas.
Rasheed, B., Stenzel, T. T., McLendon, R. E., Parsons, R. E., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Bigner, S. H. (1997) · PubMed · Cited by 388
Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X.-L., Jiang, C., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203598 · Cited by 384
Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X.-M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0343 · Cited by 371
Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB
Verdu, J., Buratovich, M. A., Wilder, E. L., & Birnbaum, M. J. (1999) · Nature Cell Biology · doi:10.1038/70293 · Cited by 368
Hu, L., Hofmann, J., Lu, Y., Mills, G. B., & Jaffe, R. B. (2002) · PubMed · Cited by 361
Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 356
Activity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
Roy, H. K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.201 · Cited by 343
Gupta, A., McKenna, W. G., Weber, C. N., Feldman, M. D., Goldsmith, J. D., Mick, R., Machtay, M. X., Rosenthal, D. I., Bakanauskas, V. J., Cerniglia, G. J., et al. (2002) · PubMed · Cited by 343
Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040316 · Cited by 343
Asselin, É., Mills, G. B., & Tsang, B. K. (2001) · PubMed · Cited by 335
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Cao, C., Subhawong, T., Albert, J. M., Kim, K. W., Geng, L., Sekhar, K. R., Gi, Y. J., & Lu, B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0802 · Cited by 332
Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2<81::aid-mc1>3.3.co;2-k · Cited by 329
Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S., & Ghosh, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0272 · Cited by 324
Gong, Y., Somwar, R., Politi, K., Balak, M., Chmielecki, J., Jiang, X., & Pao, W. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040294 · Cited by 321
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.
Malik, S. N., Brattain, M. G., Ghosh, P., Troyer, D. A., Prihoda, T. J., Bedolla, R. G., & Kreisberg, J. I. (2002) · PubMed · Cited by 321
Dai, D. L., Martinka, M., & Li, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.168 · Cited by 318
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., Le, L., Oza, A., Nicklee, T., Ho, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603419 · Cited by 317
(2000) · PubMed · Cited by 310
Yoshimoto, M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Torres, C. H., Soares, F. A., & Squire, J. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603924 · Cited by 295
Pérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292
She, Q., Solit, D. B., Basso, A., & Moasser, M. M. (2003) · PubMed · Cited by 287
Riely, G. J., Kris, M. G., Zhao, B., Akhurst, T., Milton, D. T., Moore, E., Tyson, L., Pao, W., Rizvi, N. A., Schwartz, L. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0560 · Cited by 287
Yee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
PTEN, a unique tumor suppressor gene.
Dahia, P. L. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070115 · Cited by 283
Gayed, I. W., Vu, T., Iyer, R. B., Johnson, M. M., Macapinlac, H. A., Swanston, N. M., & Podoloff, D. A. (2004) · PubMed · Cited by 282
WALKER, K. S., DEAK, M., PATERSON, A., HUDSON, K., COHEN, P., & ALESSI, D. R. (1998) · Biochemical Journal · doi:10.1042/bj3310299 · Cited by 278
(2003) · PubMed · Cited by 269
Jimenez, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.3.743 · Cited by 269
Geoerger, B., Kerr, K., Tang, C. B., Fung, K., Powell, B., Sutton, L. N., Phillips∥, P. C., & Janss, A. J. (2001) · PubMed · Cited by 261
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
Schlieman, M. G., Fahy, B. N., Ramsamooj, R., Beckett, L., & Bold, R. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601396 · Cited by 260
Kurose, K., Zhou, X.-P., Araki, T., Cannistra, S. A., Maher, E. R., & Eng, C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64681-0 · Cited by 252
Prognostic Significance of Activated Akt Expression in Pancreatic Ductal Adenocarcinoma
Yamamoto, S., Tomita, Y., Hoshida, Y., Morooka, T., Nagano, H., Dono, K., Umeshita, K., Sakon, M., Ishikawa, O., Ohigashi, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-02-1441 · Cited by 241
Wang, M. Y., Lu, K. V., Zhu, S., Dia, E. Q., Vivanco, I., Shackleford, G. M., Cavenee, W. K., Mellinghoff, I. K., Cloughesy, T. F., Sawyers, C. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4392 · Cited by 240
Mohi, M. G., Boulton, C., Gu, T.-L., Sternberg, D. W., Neuberg, D., Griffin, J. D., Gilliland, D. G., & Neel, B. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400063101 · Cited by 239
Li, D., Shimamura, T., Ji, H., Chen, L., Haringsma, H. J., McNamara, K., Liang, M.-C., Perera, S. A., Zaghlul, S., Borgman, C. L., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.005 · Cited by 238
Buck, E., Eyzaguirre, A., Brown, E., Petti, F., McCormack, S., Haley, J. D., Iwata, K. K., Gibson, N. W., & Griffin, G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0166 · Cited by 234
Nakanishi, K., Sakamoto, M., Yamasaki, S., Todo, S., & Hirohashi, S. (2005) · Cancer · doi:10.1002/cncr.20774 · Cited by 222
Tamburini, J., Chapuis, N., Bardet, V., Park, S., Sujobert, P., Willems, L., Ifrah, N., Dreyfus, F., Mayeux, P., Lacombe, C., et al. (2008) · Blood · doi:10.1182/blood-2007-03-080796 · Cited by 221
Paglin, S., Lee, N.-Y., Nakar, C., Fitzgerald, M., Plotkin, J., Deuel, B., Hackett, N., McMahill, M., Sphicas, E., Lampen, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1083 · Cited by 220
Lynch, D. K., Ellis, C. A., Edwards, P. A., & Hiles, I. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203258 · Cited by 214
Hidalgo, M., Buckner, J. C., Erlichman, C., Pollack, M. S., Boni, J. P., Dukart, G., Marshall, B., Speicher, L., Moore, L., & Rowinsky, E. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0118 · Cited by 212
Mutation analysis of the PTEN/MMAC1 gene in lung cancer
Forgacs, E., Biesterveld, E. J., Sekido, Y., Fong, K., Muneer, S., Wistuba, I. I., Milchgrub, S., Brezinschek, R., Virmani, A., Gazdar, A. F., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202070 · Cited by 202
New antitumor substances of natural origin
Douros, J., & Suffness, M. (1981) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(81)80006-0 · Cited by 202
Lu, C.-H., Wyszomierski, S. L., Tseng, L.-M., Sun, M.-H., Lan, K.-H., Neal, C. L., Mills, G. B., Hortobagyi, G. N., Esteva, F. J., & Yu, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2837 · Cited by 200
The AKT kinase is activated in multiple myeloma tumor cells
Hsu, J.-H., Shi, Y., Krajewski, S., Renner, S., Fisher, M., Reed, J. C., Franke, T. F., & Lichtenstein, A. (2001) · Blood · doi:10.1182/blood.v98.9.2853 · Cited by 196
Rahmani, M., Reese, E., Dai, Y., Bauer, C., Payne, S. G., Dent, P., Spiegel, S., & Grant, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2440 · Cited by 195
(2001) · PubMed · Cited by 193
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., Sathornsumetee, S., Herndon, J. E., Dowell, J. M., McLendon, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2215 · Cited by 191
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le Gouill, S., Richardson, P., Munshi, N. C., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2281 · Cited by 187
Gupta, A. K., Cerniglia, G. J., Mick, R., Ahmed, M. S., Bakanauskas, V. J., Muschel, R. J., & McKenna, W. G. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00214-1 · Cited by 184
Enhanced radiation damage of tumor vasculature by mTOR inhibitors
Shinohara, E. T., Cao, C., Niermann, K., Mu, Y., Zeng, F., Hallahan, D. E., & Lu, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208715 · Cited by 183
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
Ermoian, R. P., Furniss, C. S., Lamborn, K. R., Basila, D., Berger, M. S., GOTTSCHALK, A. R., Nicholas, M. K., Stokoe, D., & Haas-Kogan, D. A. (2002) · PubMed · Cited by 180
Kim, K. W., Mutter, R. W., Cao, C., Albert, J. M., Freeman, M., Hallahan, D. E., & Lu, B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607094200 · Cited by 179
Momota, H., Nerio, E., & Holland, E. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1042 · Cited by 177
Mabuchi, S., Ohmichi, M., Kimura, A., Hisamoto, K., Hayakawa, J., Nishio, Y., Adachi, K., Takahashi, K., Arimoto-Ishida, E., Nakatsuji, Y., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204042200 · Cited by 174
Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer
Albert, J. M., Kim, K. W., Cao, C., & Lu, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0400 · Cited by 173
Hill, M. M., Feng, J., & Hemmings, B. A. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00973-9 · Cited by 172
PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers
Yokomizo, A., Tindall, D. J., Drabkin, H., Gemmill, R., Franklin, W., Yang, P., Sugio, K., Smith, D. I., & Liu, W. (1998) · Oncogene · doi:10.1038/sj.onc.1201956 · Cited by 170
Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., & Terakawa, N. (2001) · PubMed · Cited by 165
Human brain tumor xenografts in nude mice as a chemotherapy model
Houchens, D. P., Ovejera, A. A., Riblet, S. M., & Slagel, D. E. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90012-3 · Cited by 163
Crul, M., Rosing, H., de Klerk, G. J., Dubbelman, R., Traiser, M., Reichert, S., Knebel, N. G., Schellens, J. H. M., Beijnen, J. H., & ten Bokkel Huinink, W. W. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00127-2 · Cited by 161
Janmaat, M. L., Rodríguez, J. A., Gallegos-Ruiz, M. I., Kruyt, F. A. E., & Giaccone, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.21290 · Cited by 161
Haritunians, T., Mori, A., O’Kelly, J., Luong, Q. T., Giles, F. J., & Koeffler, H. P. (2006) · Leukemia · doi:10.1038/sj.leu.2404471 · Cited by 158
Van Ummersen, L., Binger, K., Volkman, J., Marnocha, R., Tutsch, K., Kolesar, J., Arzoomanian, R., Alberti, D., & Wilding, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0406 · Cited by 158
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
Strömberg, T., Dimberg, A., Hammarberg, A., Carlson, K. E., Österborg, A., Nilsson, K., & Jernberg‐Wiklund, H. (2003) · Blood · doi:10.1182/blood-2003-05-1543 · Cited by 155
Martelli, A. M., Tazzari, P. L., Tabellini, G., Bortul, R., Billi, A. M., Manzoli, L., Ruggeri, A., Conte, R., & Cocco, L. (2003) · Leukemia · doi:10.1038/sj.leu.2403044 · Cited by 155
Ihle, N. T., Paine-Murrieta, G. D., Berggren, M. I., Baker, A. F., Tate, W. R., Wipf, P., Abraham, R. T., Kirkpatrick, D. L., & Powis, G. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0149 · Cited by 154
Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis.
Ruiter, G., Zerp, S. F., Bartelink, H. G. M. M., BLITTERSWIJK, W. J. V., & Verheij, M. (1999) · PubMed · Cited by 152
Edwards, E., Geng, L., Tan, J., Onishko, H. M., Donnelly, E. F., & Hallahan, D. E. (2002) · PubMed · Cited by 152
Terakawa, N., Kanamori, Y., & Yoshida, S. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100203 · Cited by 151
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
Klejman, A., Rushen, L., Morrione, A., Słupianek, A., & Skórski, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205724 · Cited by 149
Zinda, M. J., Johnson, M., Paul, J., Horn, C. L., Konicek, B. W., Lü, Z., Sandusky, G. E., Thomas, J. E., Neubauer, B. L., Lai, M. T., et al. (2001) · PubMed · Cited by 148
Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers
Kohno, T., Takahashi, M., Manda, R., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2<152::aid-gcc10>3.0.co;2-s · Cited by 147
The proteasome as a potential target for novel anticancer drugs and chemosensitizers
Landis‐Piwowar, K. R., Milacic, V., Chen, D., Yang, H., Zhao, Y., Chan, T. H., Yan, B., & Dou, Q. P. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.11.001 · Cited by 146
Somatic mutation of PTEN in bladder carcinoma
Aveyard, J. S., Skilleter, A., Habuchi, T., & Knowles, M. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690439 · Cited by 138
Molecular imaging of Akt kinase activity
Zhang, L., Lee, K. C., Bhojani, M. S., Khan, A. P., Shilman, A., Holland, E. C., Ross, B. D., & Rehemtulla, A. (2007) · Nature Medicine · doi:10.1038/nm1608 · Cited by 138
Kokubo, Y., Gemma, A., Noro, R., Seike, M., Kataoka, K., Matsuda, K., Okano, T., Minegishi, Y., Yoshimura, A., Shibuya, M., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602559 · Cited by 137
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
Wu, C., Wangpaichitr, M., Feun, L. G., Kuo, M. T., Robles, C., Lampidis, T. J., & Savaraj, N. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-25 · Cited by 126
Wanner, K., Hipp, S., Oelsner, M., Ringshausen, I., Bogner, C., Peschel, C., & Decker, T. W. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06210.x · Cited by 125
Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy
Moretti, L., Yang, E. S.-H., Kim, K. W., & Lu, J. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.05.001 · Cited by 124
A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin
Ma, P. C., Schaefer, E., Christensen, J. G., & Salgia, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1708 · Cited by 124
PRAS40 Deregulates Apoptosis in Malignant Melanoma
Madhunapantula, S. V., Sharma, A. K., & Robertson, G. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4234 · Cited by 123
Argiris, A. E., Cohen, E. E. W., Karrison, T. G., Esparaz, B. T., Mauer, A. M., Ansari, R., Wong, S. J., Lu, Y. F., Pins, M., Dancey, J. E., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2874 · Cited by 117
Ito, D., Fujimoto, K., Mori, T., Kami, K., Koizumi, M., Toyoda, E., Kawaguchi, Y., & Doi, R. (2005) · International Journal of Cancer · doi:10.1002/ijc.21532 · Cited by 117
Punt, C. J. A., Boni, J. P., Bruntsch, U., Peters, M. E. W. J., & Thielert, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg248 · Cited by 117
Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin
Lun, X. Q., Zhou, H., Alain, T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1214 · Cited by 110
Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma
Ernst, D. S., Eisenhauer, E. A., Wainman, N., Davis, M., Lohmann, R. C., Baetz, T. D., Bélanger, K., & Smylie, M. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1157-4 · Cited by 108
Rahmani, M., Yu, C., Reese, E., Ahmed, W. B., Hirsch, K. G., Dent, P., & Grant, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206646 · Cited by 107
Min, Y. H., Cheong, J., Kim, J. Y., Eom, J.-I., Lee, S., Hahn, J. S., Ko, Y. W., & Lee, M. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0174 · Cited by 107
Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis
Nam, S. Y., Lee, H. S., Jung, G., Choi, J., Cho, S. J., Kim, M. K., Kim, W. H., & Lee, B. L. (2003) · Apmis · doi:10.1111/j.1600-0463.2003.apm1111205.x · Cited by 104
Carpenter, J. T., Roche, H. H., Campone, M., Colomer, R., Jagiełło-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J. P., & Baselga, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.564 · Cited by 99
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer
Milton, D. T., Riely, G. J., Azzoli, C. G., Gomez, J. E., Heelan, R. T., Kris, M. G., Krug, L. M., Pao, W. J., Pizzo, B., Rizvi, N. A., et al. (2007) · Cancer · doi:10.1002/cncr.22816 · Cited by 98
A phase II study of perifosine in androgen independent prostate cancer
Posadas, E. M., Gulley, J. L., Arlen, P. M., Trout, A., Parnes, H. L., Wright, J., Lee, M.-J., Chung, E. J., Trepel, J. B., Sparreboom, A., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.10.2064 · Cited by 97
Antitumor Activity of Rapamycin in a Transgenic Mouse Model of ErbB2-Dependent Human Breast Cancer
Liu, M., Howes, A. L., Lesperance, J., Stallcup, W. B., Hauser, C. A., Kadoya, K., Oshima, R. G., & Abraham, R. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4589 · Cited by 97
Treeck, O., Wackwitz, B., Haus, U., & Ortmann, O. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.019 · Cited by 96
Tortora, G., Bianco, R., Daniele, G., Ciardiello, F., McCubrey, J. A., Ricciardi, M. R., Ciuffreda, L., Cognetti, F., Tafuri, A., & Milella, M. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.03.003 · Cited by 96
Rao, R. D., Mladek, A. C., Lamont, J. D., Goble, J. M., Erlichman, C., James, C. D., & Sarkaria, J. N. (2005) · Neoplasia · doi:10.1593/neo.05361 · Cited by 95
Ohta, T., Ohmichi, M., Hayasaka, T., Mabuchi, S., Saitoh, M., Kawagoe, J., Takahashi, K., Igarashi, H., Du, B., Doshida, M., et al. (2006) · Endocrinology · doi:10.1210/en.2005-1450 · Cited by 94
Chan, C. T., Metz, M. Z., & Kane, S. E. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-7715-1 · Cited by 91
Francis, L. K., Alsayed, Y. M., Leleu, X. P., Jia, X., Singha, U. K., Anderson, J. L., Timm, M., Ngo, H. T., Lu, G., Huston, A. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1331 · Cited by 91
Nyåkern, M., Cappellini, A., Mantovani, I., & Martelli, A. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0076 · Cited by 90
Carón, R. W., Yacoub, A., Li, M., Zhu, X., Mitchell, C., Hong, Y. K., Hawkins, W., Sasazuki, T., Shirasawa, S., Kozikowski, A. P., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.257.4.2 · Cited by 85
Self-citationKnowling, M., Blackstein, M. E., Tozer, R. G., Bramwell, V. H. C., Dancey, J. E., Dore, N. L., Matthews, S. W., & Eisenhauer, E. A. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-6406-7 · Cited by 84
Jimeno, A., Kulesza, P., Wheelhouse, J., Chan, A., Zhang, X., Kincaid, E., Chen, A. R., Clark, D. P., Forastiere, A. A., & Hidalgo, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603656 · Cited by 83
Dreher, T., Zentgraf, H., Abel, U. R., Kappeler, A., Michel, M., Bleyl, U., & Grobholz, R. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1004-6 · Cited by 82
A Phase 2 study of perifosine in advanced or metastatic breast cancer
Leighl, N. B., Dent, S. F., Clemons, M. J., Vandenberg, T. A., Tozer, R. G., Warr, D. G., Crump, R. M., Hedley, D. W., Pond, G. R., Dancey, J. E., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9584-x · Cited by 82
Loss of PTEN is associated with progression to androgen independence
Bertram, J., Peacock, J. W., Fazli, L., Mui, A., Chung, S. W., Cox, M., Monia, B. P., Gleave, M. E., & Ong, C. J. (2006) · The Prostate · doi:10.1002/pros.20411 · Cited by 81
Vink, S. R., Schellens, J. H. M., Beijnen, J. H., SINDERMANN, H., Engel, J., Dubbelman, R., Moppi, G., Hillebrand, M. J. X., Bartelink, H. G. M. M., & Verheij, M. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.07.032 · Cited by 77
Santos, S. C. R., Penard‐Lacronique, V., Bouchaert, I., Monni, R., Bernard, O., Gisselbrecht, S., & Gouilleux, F. (2001) · Oncogene · doi:10.1038/sj.onc.1204308 · Cited by 76
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
Bailey, H. H., Mahoney, M. R., Ettinger, D. S., Maples, W. J., Fracasso, P. M., Traynor, A. M., Erlichman, C., & Okuno, S. H. (2006) · Cancer · doi:10.1002/cncr.22308 · Cited by 75
Stephan, S., Datta, K., Wang, E., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0808 · Cited by 74
Shingu, T., Yamada, K., Hara, N., Moritake, K., Osago, H., Terashima, M., Uemura, T., Yamasaki, T., & Tsuchiya, M. (2003) · PubMed · Cited by 74
Chiang, C.-T., Way, T., & Lin, J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0107 · Cited by 71
LY294002 and rapamycin co‐operate to inhibit T‐cell proliferation
Breslin, E. M., White, P. C., Shore, A. M., Clement, M., & Brennan, P. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706061 · Cited by 65
RAD001 (Everolimus) Improves the Efficacy of Replicating Adenoviruses that Target Colon Cancer
Homicskó, K., Lukashev, A. N., & Iggo, R. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0309 · Cited by 64
Marsh, R., Lima, C. M. R., Levy, D. E., Mitchell, E. P., Rowland, K. M., & Benson, A. B. (2007) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000251235.46149.43 · Cited by 63
Kasukabe, T., Okabe‐Kado, J., Kato, N., Sassa, T., & Honma, Y. (2005) · Breast Cancer Research · doi:10.1186/bcr1344 · Cited by 62
Puduvalli, V. K., Sampath, D., Bruner, J. M., Nangia, J. R., Xu, R., & Kyritsis, A. P. (2005) · APOPTOSIS · doi:10.1007/s10495-005-6078-3 · Cited by 60
Feun, L. G., Blessing, J. A., Barrett, R. J., & Hanjani, P. (1993) · American Journal of Clinical Oncology · doi:10.1097/00000421-199312000-00010 · Cited by 59
Stokoe, D. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00303-7 · Cited by 58
Li, X., Luwor, R. B., Lü, Y., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209075 · Cited by 57
Steinbach, J. P., Eisenmann, C., Klumpp, A., & Weller, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.175 · Cited by 56
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule.
Feun, L. G., Savaraj, N., Bodey, G. P., Lu, K., Yap, B. S., Ajani, J. A., Burgess, M. A., Benjamin, R. S., McKelvey, E. M., & Krakoff, I. H. (1984) · PubMed · Cited by 55
Gemmill, R. M., Zhou, M., Costa, L. J., Korch, C. T., Bukowski, R. M., & Drabkin, H. A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602646 · Cited by 54
Festuccia, C., Muzi, P., Millimaggi, D., Biordi, L. A., Gravina, G. L., Speca, S., Angelucci, A., Dolo, V., Vicentini, C., & Bologna, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00986 · Cited by 54
Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer
Sarkaria, J. N., Schwingler, P. M., Schild, S. E., Grogan, P. T., Mladek, A. C., Mandrekar, S. J., Tan, A. D., Kobayashi, T., Marks, R. S., Kita, H., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3180cc2587 · Cited by 51
Regulation of the PRL Promoter by Akt through cAMP Response Element Binding Protein
Hayakawa, J., Ohmichi, M., Tasaka, K., et al. (2002) · Endocrinology · doi:10.1210/endo.143.1.8586 · Cited by 51
Gills, J. J., Castillo, S. S., Zhang, C., Petukhov, P. A., Memmott, R. M., Hollingshead, M. G., Warfel, N. A., Han, J., Kozikowski, A. P., & Dennis, P. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701108200 · Cited by 51
Self-citationGills, J. J., Holbeck, S. L., Hollingshead, M. G., Hewitt, S. M., Kozikowski, A. P., & Dennis, P. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0484 · Cited by 48
Self-citationThallinger, C., Poeppl, W., Pratscher, B., Mayerhöfer, M., Valent, P., Tappeiner, G., & Joukhadar, C. (2007) · Pharmacology · doi:10.1159/000101008 · Cited by 42
Hjelmeland, A. B., Lattimore, K. P., Fee, B. E., Shi, Q., Wickman, S., Keir, S. T., Hjelmeland, M. D., Batt, D. B., Bigner, D. D., Friedman, H. S., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0155 · Cited by 41
Thallinger, C., Werzowa, J. M., Poeppl, W., Kovar, F. M., Pratscher, B., Valent, P., Quehenberger, P., & Joukhadar, C. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700872 · Cited by 35
Zafar, S. Y., Bendell, J. C., Lager, J. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3097 · Cited by 33
Pacey, S., Rea, D., Steven, N. M., Brock, C., Knowlton, N. S., Shand, N., Hazell, K., Zoellner, U., O’Donnell, A. E., & Judson, I. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3120 · Cited by 32
Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer Cells
Costa, L. J., Gemmill, R. M., & Drabkin, H. A. (2007) · Urology · doi:10.1016/j.urology.2007.01.053 · Cited by 31
Cited by
Global signatures of protein and mRNA expression levels
de Sousa Abreu, R., Penalva, L. O., Marcotte, E. M., & Vogel, C. (2009) · Molecular BioSystems · doi:10.1039/b908315d · Cited by 1,248
Role of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
The PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878
Metadata
- Authors
- LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 11
- Issue
- 1-2
- Pages
- 32-50
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2074433596
- Cited by
- 801
- References
- 209
- FWCI
- 24.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.